1. Home
  2. CBIO vs JILL Comparison

CBIO vs JILL Comparison

Compare CBIO & JILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.94

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

Logo J. Jill Inc.

JILL

J. Jill Inc.

HOLD

Current Price

$15.26

Market Cap

233.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
JILL
Founded
2003
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
198.9M
233.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CBIO
JILL
Price
$10.94
$15.26
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$25.60
$18.50
AVG Volume (30 Days)
105.4K
138.9K
Earning Date
02-23-2026
12-10-2025
Dividend Yield
N/A
2.10%
EPS Growth
N/A
N/A
EPS
N/A
2.19
Revenue
N/A
$600,981,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.76
P/E Ratio
N/A
$6.94
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$13.32
52 Week High
$21.40
$28.94

Technical Indicators

Market Signals
Indicator
CBIO
JILL
Relative Strength Index (RSI) 33.72 57.98
Support Level $10.86 $13.68
Resistance Level $11.68 $14.49
Average True Range (ATR) 0.76 0.61
MACD -0.16 0.09
Stochastic Oscillator 11.67 90.75

Price Performance

Historical Comparison
CBIO
JILL

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About JILL J. Jill Inc.

J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.

Share on Social Networks: